Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) shares surged 12.38 percent to close at $5.81 a share Monday. The stock traded between $5.12 and $5.96 on volume of 4.20 million shares traded. The company reported positive proof-of-concept data for its lead nucleotide Prodrug, IDX21437. Shares of Idenix Pharmaceuticals are down approximately 3.0 percent year-to-date.
Get more information on Idenix Pharmaceuticals and free access to the in-depth equity report at:
Puma Biotechnology Inc. (NYSE: PBYI) shares declined 18.30 percent to close at $86.94 a share Monday. The stock traded between $78.96 and $118.22 on volume of 1.59 million shares traded. The company recently present results from the Phase II clinical trial of Puma's investigational drug PB272 at the American Association for Cancer Research (AACR) Annual Meeting. Shares of Puma Biotechnology are down approximately 16.0 percent year-to-date.
Get more information on Puma Biotechnology and free access to the in-depth equity report at:
Select Medical Holdings Corporation (NYSE: SEM) shares increased 4.29 percent to close at $13.13 a share Monday. The stock traded between $12.82 and $13.38 on volume of 1.42 million shares traded. RBC Capital Markets have recently upgraded its rating on the company to "outperform" from "sector perform". Shares of Select Medical Holdings are up approximately 13.0 percent year-to-date.
Get more information on Select Medical Holdings and free access to the in-depth equity report at:
Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares increased 7.29 percent to close at $24.73 a share Monday. The stock traded between $21.75 and $25.41 on volume 2.21 million shares traded. The company is scheduled to present a company overview at the 2014 Annual Needham Healthcare Conference on April 9th. Shares of Sarepta Therapeutics are up approximately 20.0 percent year-to-date.
Get more information on Sarepta Therapeutics and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities